Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810Gerald S. Falchook, Matthew G. Fury, Carlo Bifulco et al.|Journal for ImmunoTherapy of Cancer|2016Cited by 151
Phase II study of cemiplimab, a human monoclonal anti-PD-1, in patients with advanced basal cell carcinoma (BCC) who experienced progression of disease on, or were intolerant of prior hedgehog pathway inhibitor (HHI) therapyKarl D. Lewis, Anjali Narwal, Matthew G. Fury et al.|Annals of Oncology|2018Cited by 3